Point72 Europe London LLP Has $6.51 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Point72 Europe London LLP reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 70,494 shares of the biopharmaceutical company's stock after selling 34,903 shares during the period. Point72 Europe London LLP's holdings in Gilead Sciences were worth $6,512,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC boosted its holdings in Gilead Sciences by 21.6% during the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after buying an additional 7,157,113 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Gilead Sciences by 3.1% in the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock valued at $3,293,822,000 after acquiring an additional 1,058,331 shares during the period. Geode Capital Management LLC boosted its stake in Gilead Sciences by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock worth $2,608,337,000 after acquiring an additional 749,047 shares during the last quarter. Norges Bank acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $1,789,254,000. Finally, Northern Trust Corp increased its stake in Gilead Sciences by 19.7% in the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock valued at $1,377,707,000 after purchasing an additional 2,458,954 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on GILD. Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research report on Friday, April 25th. DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective for the company in a research note on Thursday, February 13th. Finally, Oppenheimer reduced their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $98.38 on Thursday. The stock's 50-day moving average is $106.33 and its 200-day moving average is $99.50. The stock has a market cap of $122.50 billion, a P/E ratio of 265.89, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same period in the previous year, the business earned ($1.32) EPS. The business's quarterly revenue was down .3% compared to the same quarter last year. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 3.21%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total transaction of $260,225.00. Following the completion of the sale, the chief financial officer now owns 169,061 shares in the company, valued at $17,597,559.49. The trade was a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 22,929 shares of company stock worth $2,644,895 in the last 90 days. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.